Impact of white matter hypodensities on outcome after intracerebral hemorrhage.

Cerebrovascular diseases Intracerebral hemorrhage Stroke outcome White matter hypodensities

Journal

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
ISSN: 1532-8511
Titre abrégé: J Stroke Cerebrovasc Dis
Pays: United States
ID NLM: 9111633

Informations de publication

Date de publication:
Feb 2023
Historique:
received: 31 08 2022
revised: 27 10 2022
accepted: 27 11 2022
pubmed: 7 12 2022
medline: 11 1 2023
entrez: 6 12 2022
Statut: ppublish

Résumé

White matter hypodensities (WMH), a surrogate of small vessel disease, associate with cognitive decline and stroke risk. The impact of WMH on functional outcome after intracerebral hemorrhage (ICH) has differed between studies. We aimed to examine factors associated with the severity of WMH in ICH, and whether there is an independent association between the extent of WMH and outcome. This was a prospective study of consented patients with non-traumatic primary ICH, admitted to the Helsinki University Hospital between May 2014 and December 2018. To evaluate the extent of the WMH, modified van Swieten score of the side contralateral to the ICH was obtained. Patients were grouped into 3 categories of the scores. We performed univariate and multivariable analyses to find out factors associated with the severity of WMH, and whether WMH associate with functional outcome and mortality up to 12 months, adjusted for the known major outcome predictors. In our cohort of 417 ICH patients, WMH severity associated with older age, female sex, admission National Institutes of Health Stroke Scale (NIHSS) points, and signs of previous ischemic stroke on CT. We found an independent association between WMH severity and poor functional outcome at 3 months (OR 1.72, 95% CI 1.27-2.33), and 1 year (OR 2.16, 95% CI 1.57-2.95), and mortality at 1 year (OR 1.91, 95% CI 1.29-2.85). In our ICH patients, vascular comorbidities and older age associated with the presence of WMH, which, in turn, strongly associated with poor functional outcome.

Identifiants

pubmed: 36473394
pii: S1052-3057(22)00611-5
doi: 10.1016/j.jstrokecerebrovasdis.2022.106919
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106919

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest HS reports grants from Maire Taponen Foundation, Biomedicum Helsinki Foundation, and The Finnish Medical Foundation. MT reports speaker honoraria from Sanofi Genzyme. LT, NM-M, PV, GS and DS report no disclosures relevant to the manuscript.

Auteurs

Hanne Sallinen (H)

Department of Neurology and Neurosciences, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. Electronic address: hanne.sallinen@helsinki.fi.

Liisa Tomppo (L)

Department of Neurology and Neurosciences, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. Electronic address: liisa.maaria.tomppo@hus.fi.

Nicolas Martinez-Majander (N)

Department of Neurology and Neurosciences, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. Electronic address: nicolas.martinez-majander@hus.fi.

Pekka Virtanen (P)

Department of Radiology, Helsinki University Hospital and Helsinki University, Helsinki, Finland. Electronic address: pekka.virtanen@hus.fi.

Gerli Sibolt (G)

Department of Neurology and Neurosciences, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. Electronic address: gerli.sibolt@hus.fi.

Marjaana Tiainen (M)

Department of Neurology and Neurosciences, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. Electronic address: marjaana.tiainen@hus.fi.

Daniel Strbian (D)

Department of Neurology and Neurosciences, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. Electronic address: daniel.strbian@hus.fi.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH